Ajay Major, MD, MBA

Announcing the first paper of @TheLancetHaem Commission on Adverse Events, with @BiostatGirl & @GitaThanaMD. We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination. sciencedirect.com/science/articl… Thread ⬇️ 🧵

Very proud of my @ClevelandClinic mentor Dr. @BrianHill_MDPhD and former co-fellow Dr Taylor Brooks (@RoswellPark contributed) and their large study on outcomes with BSAbs in #DLBCL. Great option but more research greatly needed especially post #CART #lymsm

Bispecifics in B-ALL - Great Bispecifics in LBCL - a little disappointing. Do we need trispecifics or bispecific + X combos to sensitize? #lymsm

Tough real world outcomes for bispecifics.

Interesting that RWD in CART do look similar to the pivotal trials, which is totally different from this data. Then again, how “real world” is the RDW from CART? Also, some of the pts are s/p CAR T tx.

Our @CULymphoma faculty Dr. @majorajay contributed to a large multicenter study of bispecific antibody therapy outcomes, published @BloodPortfolio. #lymsm #tcellrx cc @CUAnschutz @CUCancerCenter @CUHematology

I am happy to announce I was selected by @ASH_Hematology to receive the ASH HONORS Award! Excited for this project studying PET/CT radiomics in DLBCL. Grateful to @mana1981 for her mentorship and ASH for the support! #ASHAwards #Fight4Hematology @CULymphoma @CUDeptMedicine

Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm vjhemonc.com/video/amtyhj8p…

I spent WAY too long last week in oncology clinic manually generating chemotherapy dates and appointments for schedulers. So, in a fit of rage, I vibe-coded this simple app to forever do this for me... and you! #rstats 👨‍💻 @TheCodingDocs 📊 Free app --> thecodingdocs.com/clincal/chemo-…

Congratulations to our @CULymphoma lead Dr. @mana1981 on her first-author publication in @JCO_ASCO about the 3-year follow-up of TRANSFORM! ascopubs.org/doi/10.1200/JC… #lymsm #tcellrx

This is a big deal because it will also relax strategies globally and hopefully make treatment of patients more flexible and patient cantered.

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm fda.gov/vaccines-blood…

Waleed Alduaij at #icmlugano last week presented this well conducted retrospective study from British Columbia on double hit lymphoma, suggesting a large benefit from DA EPOCHR vs RCHOP. But the PFS separation is very early, mostly <3 months...

Top Oncologists from 18th International Conference on Malignant Lymphoma (@icmlugano 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | @graham74GC | @majorajay |…

🧠 VTE doesn’t end at discharge. Patients often face long-term symptoms & distress, too often missed. PROMs help us hear what matters to them. 🔸 Ask 🔸 Use actively 🔸 Guide care Great insights from Attend-PE & @ISTH2025 #Thrombosis #PatientCenteredCare

The new debate in advanced stage HL treatment. #18ICML #ICML2025

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

Reinforces that getting patient to ASCT is important. In my view this trumps CAR-T (if chemosensitive of course)

🚨 PRiZM+: Zanubrutinib monotherapy in rrPCNSL 🔹 ORR 55%, CR/CRu 35% (CR 15%) by central review 🔹 mPFS 6.9 mo | 1y PFS 37% 🔹 mOS 13 mo | 1y OS 53% 🔹 Zanu detectable in CSF (PK) 👉 ZanuTafaLen triplet (Cohort 2) opening soon — data awaited #ICML2025 #PCNSL #lymsm